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The growing use of molecular diagnostics poses a wide range of issues and questions 
concerning informed consent that researchers, health care providers, and others will 
increasingly need to address. Molecular diagnostics are advancing more rapidly than our 
ability to decide how best to respond to their complex medical, ethical, legal, psychological, 
and social implications. Although some of these issues resemble those posed by prior tests, 
the newness and ever-faster spread of these tests, the advent of large-scale electronic 
databases, and the many inherent uncertainties involved present new challenges and 
dilemmas that require careful attention to determine how best to proceed. Obtaining 
appropriate informed consent will require considerable resources, which many researchers 
and providers may not fully appreciate. For example, for whole genome sequencing (WGS)2 
and whole exome sequencing (WES), most researchers have indicated that they were willing 
to spend 30 minutes or less on obtaining informed consent (1). Yet the complexity of the 
information involved will probably often require significantly longer interactions.
The Basics of Informed Consent
As articulated in the 1946 Nuremberg Code (2), informed consent is crucial in research 
because it ensures that investigators respect and protect the autonomy and rights of patients 
and research study participants. The Declaration of Helsinki (1964; amended in 2013) and 
the Belmont Report (1979) extended, emphasized, and elaborated on the importance of 
informed consent in all of health care (3, 4). Patients and participants must ordinarily be 
appropriately informed about any procedures they are undergoing related to diagnosis, 
treatment, or research and must consent to these procedures. Subjects should not just sign a 
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form, but understand the content, including the purpose, risks and benefits, alternative 
options, if any, and plans for confidentiality (5).
Yet challenges arise. Consent forms often end up being too long and complicated for many 
participants to understand. Although most universities require that these forms be written at 
no more than an eighth-grade reading level, 92% of these institutions fail to meet this 
standard (6). Frequently, problems emerge because institutions and private companies 
funding a study want these forms to serve as legal documents—to protect themselves— 
rather than having a primary purpose of educating patients about the relevant issues (6).
Challenges in Consenting for Molecular Diagnostics
Several particular challenges emerge in obtaining appropriate informed consent for 
individuals undergoing molecular diagnostic tests. These tests may be new, and their 
validity, reliability, implications, and present and future utility may be unclear. Hence, the 
potential benefits and risks of such relatively new tests and procedures cannot always be 
wholly known.
INTERPRETATION OF MOLECULAR DIAGNOSTIC INFORMATION
The results of certain molecular diagnostic assays may remain uncertain. For instance, 
genetic markers may be found but be only partially penetrant or predictive, or difficult to 
interpret, yet need to be conveyed to the patient in a way that he or she can sufficiently 
understand. With WGS/WES, some results will indicate variants of uncertain significance, 
posing challenges for informed consent of whether, when, and how to convey the possibility 
and meaning of such ambiguous information to patients (7). A variant may have been 
reported once or twice in the literature or have inconsistent or unclear relationships to 
phenotypes. Rigorous, consistent criteria need to be developed for determining and reporting 
which variants are pathologic (8). Such efforts will most likely take a considerable amount 
of time, and scientific understandings of the pathogenicity of many variants will surely 
evolve substantially over the years, raising questions of what informed consent forms should 
state about these phenomena beforehand. Consent forms can specify that only findings with 
a certain degree of certainty will be returned, but ambiguities can persist. Patients vary in 
their desires for and abilities to understand such data, based on various factors (9). Research 
is being conducted to ascertain patients’ preferences and understandings of several different 
types of information and scenarios (e.g., returning information on carrier status; 
pharmacogenomics; and tests that are highly penetrant, but not clinically actionable) (1).
INCIDENTAL FINDINGS
WGS/WES can also reveal secondary or incidental findings, posing dilemmas. In 2013, the 
American College of Medical Genetics (ACMG) recommended that laboratories report to 
physicians who order clinical sequencing tests the presence or absence of 56 so-called 
actionable genes associated with 23 serious disorders (10). Patients (or their caregivers) 
would not have a choice. Parents would thus be given the results for infants who were 
tested. In April 2014, ACMG revised its recommendations, allowing patients to opt out (11). 
Ongoing questions will continue to surface, however, as researchers determine that 
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additional genes are highly predictive and actionable, and if so, to what degree. Consent 
forms also need to address whether future tests results—whether intended or incidental—
may be conducted on specimens, and if so, whether patients will receive these results, and if 
so, which.
Patients may also want to learn the results of various other tests that may be actionable 
personally, but not medically. That is, individuals at risk of Huntington disease may want to 
know whether they have this mutation, because if so they would alter their life plans, 
perhaps deciding neither to have children nor to “save all their money for the future,” but to 
enjoy their lives as fully as possible now because their lifespans will be limited. Patients 
may also be told initially that a finding is clinically significant, though subsequent research 
shows that not to be the case.
Presumably, arrangements will thus need to be made to be able to contact patients or 
research subjects in the future. ACMG has issued practice guidelines concerning several 
other tests that are not highly predictive and actionable (e.g., regarding Alzheimer disease 
and carrier status). Generally for such tests—and regarding personalized medicine more 
broadly—appropriate genetic counseling, including education about possible risks and 
benefits of testing and ascertainment of patients’ understandings and preferences, is crucial 
(12).
WHEN THE PATIENT IS UNABLE TO GIVE CONSENT
Questions emerge when individuals cannot consent for themselves (e.g., due to cognitive 
impairment). In such cases, a spouse or next of kin can serve as a surrogate. With prenatal or 
pediatric WGS/WES, additional questions surface, e.g., how much genetic information the 
parents want and how to assess the child’s best interests. Children can assent, but not 
consent, and a legal guardian is thus necessary. Still, providers and researchers must 
determine exactly whether, what, and how to explain molecular diagnostic tests to children, 
and do so with sensitivity and care. Children should receive relevant age-appropriate 
information; both medically and psychologically, the benefits of testing should outweigh the 
harms (e.g., discrimination, anxiety, and confusion).
Noninvasive prenatal genetic testing of cell-free DNA and fetal cells poses additional 
dilemmas (13). The noninvasiveness of such testing offers advantages over amniocentesis 
(which is more invasive), but patients may have concerns about possible false positives and 
false negatives (14) and what specific genes to assay. Dilemmas emerge, too, concerning 
possible terminations of pregnancies: which tests results warrant such termination and where 
to draw the line (e.g., whether incidental/secondary findings should be sought) (15, 16). 
Providers should proceed with care, counseling prospective parents appropriately.
DISCLOSURES TO OTHERS
Given fears of discrimination, consent forms should also specify who else will have access 
to test results. In the US, the Genetic Information Non-Discrimination Act protects against 
discrimination in most health insurance, but not in life, disability, or long-term care 
insurance or in schools. Some individual states have anti-discrimination laws, but these laws 
vary widely.
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Many patients will want to know who else will see their data; whether the results will be 
posted online or otherwise be available, and if so, to whom; and what other phenotypic data, 
if any, will be included. Schools may also want to see genetic information. Yet, if genetic 
markers are included that are associated with somewhat increased risks of certain conditions, 
such as autism, questions arise of how the school will react: e.g., whether teachers might as 
a result spend less time with a particular student, even though he or she might never develop 
the disorder.
BLURRING BOUNDARIES BETWEEN RESEARCH AND CLINICAL CARE
Distinctions between clinician and research activities are also blurring because of so-called 
learning health systems (17), in which knowledge generation is embedded into the practice 
of healthcare delivery improvement (18). Traditionally, research and clinical interventions 
differ (given differing goals of knowledge production vs therapeutic benefits), but these 
boundaries are becoming hazy. For many cancers, the only treatment is experimental. Many 
medical centers are seeking to build biobanks of diagnostic and other medical information 
for both clinical and research purposes. Questions emerge of who would have access to test 
results, how much phenotypic data researchers should receive without obtaining specific 
informed consent, whether test results conducted as part of research should ever be included 
in electronic health records, and whether molecular diagnostic tests performed for research 
purposes should ever be disclosed to the patient, and if so, when.
Consent forms may also need to convey who owns specimens and data collected from 
individuals. For biobanks, for instance, consent may need to discuss whether patients or 
study participants can later arrange to have their information removed, and if so, how.
Moving into the Future
Challenges concerning consent will require ongoing attention and discussion among relevant 
stakeholders: patients, providers, researchers, laboratory officials, policymakers, and others. 
These groups will also need ongoing education about these evolving issues. Although 
appropriate informed consent is essential (1), researchers and providers may lack the 
necessary time to obtain it. Genetic counselors can help, but are in short supply and 
generally underfunded by insurance companies. Governmental policies thus should change 
to ensure adequate insurance coverage for these complex discussions.
Additional research is also critical to assess patient and provider decision-making about 
these dilemmas. As molecular diagnostics advances, additional efforts will be vital to 
address these complexities, to balance disease prevention and treatment with avoidance of 
stigma and discrimination. As much as possible, physicians, researchers, patients, 
institutional review boards, policymakers, and others will need to be prepared to address 
these ever-unfolding challenges.
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